UBS maintains Altria Group at Buy, raises price target to $83 from $79

UBS kept its Buy rating on Altria Group and increased its price target to $83 from $79, suggesting a 6.4% upside from the Oct 30 close of $78.03, according to the company.

Original reporting
Published Oct 31, 2026, 1:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 1:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Altria Group at Buy, raises price target to $83 from $79 — source image
Decision brief

The 30-second read

$MOBullishMed
01

Why it matters

The price target increase may prompt short-term buying, but long-term performance remains tied to industry trends.

02

Market read

A modest analyst upgrade that could generate short-term upside for MO.

03

What to watch

Potential impact of declining smoking rates and shifting consumer preferences.

Relevance 6/10Novelty 6/10Timing: immediate

Background

Altria Group (MO) is a leading tobacco company; analyst upgrades can influence its stock price.

Company-level read

Ticker impact

$MOBullishMedium confidence
Context

UBS raised Altria Group's price target to $83 from $79, indicating a bullish outlook.

Expected impact

potential modest upside as the market prices in the higher target

Evidence & confidence

Target raise of 5.1% signals improved expectations, likely to attract buying pressure.

Market effects

May lift sentiment in the tobacco sector as peers could see similar analyst upgrades.

Limited to US equities, no broader regional effect.

Low; impact confined to Altria and related tobacco stocks.

Counterpoint

Target raise could be premature if regulatory or litigation risks intensify.

Key entities

  • UBS

    Investment bank that raised the price target.

  • Altria Group

    US-listed tobacco company (ticker MO).

Related articles

$MOHighAI 8/10

Why Did MO, GILD, XOM Stocks Surge To 52-Week Highs Last Week?

Altria (MO), Gilead (GILD), and ExxonMobil (XOM) reached 52-week highs after strong Q3 results. MO reported $1.52 EPS, raised guidance, and increased buybacks. GILD exceeded revenue/earnings expectations, boosting HIV growth outlook. XOM posted $4.23 EPS, raised dividend, and maintained buyback plan. All three stocks gained 1-3% on the day.

$MOHighAI 8/10

America’s Greatest Dividend Posts Strong Earnings

Altria (MO) reported Q3 revenue of $6.1B (+1% YoY) and EPS of $1.51 (+7% YoY), beating expectations. The company raised its full-year earnings guidance, citing strong performance. Shares rose 6% over two days and are up 33% YTD. CEO Sal Mancuso highlighted confidence in the full-year plan. Marlboro, with a 40% U.S. market share, drives most revenue. Other high-yield companies like UPS, Kraft Heinz, and General Mills face economic sensitivity and competition.

$MOMed

Goldman Sees More Upside in Altria After Strong Quarter

Goldman Sachs raised its price target for Altria (MO) to $83 from $77, citing better-than-expected Q3 earnings and revenue. Adjusted EPS was $1.52, beating estimates, and revenue reached $6.13B. Management increased its 2026 EPS growth outlook. Goldman expects continued benefits from tax drawbacks and a manufacturing agreement with Philip Morris. MO stock is up 40% year-to-date.

$MOHighAI 8/10

UBS raises Altria stock price target to $83 on strong quarter

UBS raised its price target on Altria Group (NYSE:MO) to $83, citing strong Q3 2026 revenue growth of 3.6% and raised EPS guidance. The stock trades near its 52-week high, up 43% over the past year. Altria's dividend yield is 5.79%, and it has raised dividends for 16 consecutive years. Recent earnings beat estimates, with EPS of $1.52 and revenue of $6.13 billion. Goldman Sachs and BofA Securities also raised their price targets.

$MOHighAI 8/10

What Just Happened To Altria Stock?

Altria (MO) shares rose 5.2% on October 29, 2026, after beating Q3 earnings estimates and raising its full-year guidance. The company reported adjusted earnings of $1.52 per share on $5.44 billion in revenue, exceeding forecasts. Management raised its 2026 earnings outlook to $5.66-$5.74 per share, up from prior guidance. The stock closed at $76.75, its highest in a year, with a 29.5% return over the past 12 months.